|
KMID : 1039320190190010074
|
|
Journal of Liver Cancer
2019 Volume.19 No. 1 p.74 ~ p.78
|
|
|
A Case of Achieving Partial Remission with the Combination of Sorafenib and Nivolumab in a Patient with Hepatocellular Carcinoma Showing Disease Progression after Nivolumab Therapy
|
|
Hwang Sang-Youn
Lee Seon-Mi
Im Jung-Woo
Jeon Ki-Jeong
Choi Cheol-Won
Kim Kyung-Su
Jeon Wan
|
|
|
Abstract
|
|
|
|
Sorafenib is a well-known approved systemic therapeutic agent used in patients with advanced hepatocellular carcinoma (HCC). Regorafenib and nivolumab are approved as second-line therapeutic drugs in patients showing disease progression after sorafenib therapy. However, there is no established third- or fourth-line therapy in patients with progression after regorafenib or nivolumab treatment. Recently, the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICPIs) has been attempted as a firstline treatment strategy in advanced HCC patients based on the hypothesis that combination therapy may overcome resistance in ICPI monotherapy. On the basis of this suggestion, we herein describe the case of an HCC patient demonstrating macrovascular invasion, whereby partial remission was achieved via the combination of sorafenib and nivolumab following disease progression after nivolumab therapy. Further studies on the combination of TKIs and ICPIs are necessary to determine ways to manage HCC patients showing disease progression after ICPI therapy.
|
|
|
KEYWORD
|
|
|
Hepatocellular carcinoma, Sorafenib, Nivolumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|